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ABSTRACT
Objective To assess associations of health- related 
quality of life (HRQoL) with patient profile, resource use, 
cardiovascular (CV) events and mortality in stable patients 
post- myocardial infarction (MI).
Methods The global, prospective, observational TIGRIS 
Study enrolled 9126 patients 1–3 years post- MI. HRQoL 
was assessed at enrolment and 6- month intervals 
using the patient- reported EuroQol-5 dimension (EQ- 
5D) questionnaire, with scores anchored at 0 (worst 
possible) and 1 (perfect health). Resource use, CV events 
and mortality were recorded during 2- years’ follow- up. 
Regression models estimated the associations of index 
score at enrolment with patient characteristics, resource 
use, CV events and mortality over 2- years’ follow- up.
Results Among 8978 patients who completed the EQ- 5D 
questionnaire, 52% reported ‘some’ or ‘severe’ problems 
on one or more health dimensions. Factors associated 
with a lower index score were: female sex, older age, 
obesity, smoking, higher heart rate, less formal education, 
presence of comorbidity (eg, angina, stroke), emergency 
room visit in the previous 6 months and non- ST- elevation 
MI as the index event. Compared with an index score of 
1 at enrolment, a lower index score was associated with 
higher risk of all- cause death, with an adjusted rate ratio 
of 3.09 (95% CI 2.20 to 4.31), and of a CV event, with 
a rate ratio of 2.31 (95% CI 1.76 to 3.03). Patients with 
lower index score at enrolment had almost two times as 
many hospitalisations over 2- years’ follow- up.
Conclusions Clinicians managing patients post- acute 
coronary syndrome should recognise that a poorer HRQoL 
is clearly linked to risk of hospitalisations, major CV events 
and death.
Trial registration number  ClinicalTrials. gov Registry 
(NCT01866904) (https:// clinicaltrials. gov).
INTRODUCTION
Improved survival following myocardial 
infarction (MI) has encouraged interest in 
identifying factors that are associated with 
subsequent cardiovascular (CV) events.1 
Clinicians require evidence about health- 
related quality of life (HRQoL) to inform 
clinical decisions for patients with stable 
coronary artery disease (CAD). Generic tools 
such as the EuroQol-5 dimension (EQ- 5D)2 
can provide useful insights into a patient’s 
well- being and prognosis, including after MI, 
beyond those offered by disease- specific tools, 
such as the Seattle Angina Questionnaire.2 3
A systematic review of HRQoL for patients 
with stable CAD, 1–3 years after MI,4 found 
major issues with published studies, in 
that they did not report the approach to 
assessing HRQoL,5–7 followed up patients 
for short time periods (up to 1 year post- 
MI)5–10 and included small samples of 
patients (≤2000),6 7 9 10 recruited from few 
countries.7–11 Munyombwe et al identified 
some factors associated with lower HRQoL, 
including advancing age and presentation 
with non- ST- elevation myocardial infarc-
tion (NSTEMI).5 Pocock et al found that 
EQ- 5D index score at hospital discharge 
Key questions
What is already known about this subject?
 ► Patients’ self- reported health- related quality of life 
(HRQoL) can be assessed using the EuroQol-5 di-
mension (EQ- 5D) for patients with stable coronary 
artery disease following myocardial infarction (MI).
What does this study add?
 ► This study finds that a lower EQ- 5D index score was 
associated with clinical and demographic factors 
assessed 1–3 years post- MI, and with subsequent 
hospitalisations, cardiovascular (CV) events and all- 
cause death.
How might this impact on clinical practice?
 ► Clinicians managing patients after acute coronary 
syndrome should recognise that patient’s self- 
reported HRQoL is strongly associated with CV 
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following MI was an independent predictor of subse-
quent outcomes.12 13 While these previous studies showed 
that the EQ- 5D can report HRQoL in populations with 
stable CAD, little research has assessed whether HRQoL 
predicts subsequent clinical outcomes and resource use.
This article reports HRQoL for patients enrolled 1–3 
years post- MI in a prospective, global registry. We aimed 
to: (1) assess the association of patient characteristics 
with HRQoL; (2) estimate the association of HRQoL 
with resource use, CV events and all- cause death; and 
(3) assess the effect of CV events on change in HRQoL 
between enrolment and 1- year’s follow- up.
METHODS
Study design
TIGRIS (long- Term rIsk clinical manaGement and 
healthcare Resource utilization of stable coronary 
artery dISease in post- myocardial infarction patients) is 
a prospective, global registry of 9126 patients enrolled 
1–3 years post- MI, during June 2013–November 2014, 
from 369 centres across 25 countries in Europe, North 
America, Latin America, Asia and Australia, who were 
followed up for 2 years. Details of the TIGRIS Study have 
been reported.14 15 In brief, patients included were aged 
≥50 years with stable CAD, a documented history of MI 
occurring 1–3 years prior to enrolment and at least one of 
the following risk factors: age ≥65 years, diabetes mellitus 
requiring medication, history of a second prior MI, angi-
ographic evidence of multivessel CAD and/or chronic 
non- end- stage kidney disease. Baseline data at enrolment 
included relevant medical history, demographics, details 
regarding the index MI before enrolment, and varia-
bles from routine physical examination and laboratory 
testing, where available.
Data collection and outcome measures
Patients were contacted every 6 months over the follow- up 
period, either by telephone or hospital visit. At each 
contact, patients were asked to complete the EQ- 5D- 3L 
survey instrument.2 16 The EQ- 5D- 3L is a generic HRQoL 
Figure 1 (A) Distributions of the EQ- 5D items and (B) the consequent EQ- 5D index score and VAS score in 8978 patients at 
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Table 1 Univariate associations of EQ- 5D index score and EQ- 5D VAS score by patient characteristics
N
EQ- 5D index score, mean 
(SD) P value EQ- 5D VAS score, mean (SD) P value
Age (years)
  50–60 2004 0.86 (0.21) <0.001 76.50 (17.57) <0.001
  60–70 3442 0.86 (0.20) 77.22 (16.50)
  70–80 2885 0.83 (0.21) 75.09 (16.62)
  80+ 647 0.77 (0.23) 72.42 (17.89)
Sex
  Male 6827 0.87 (0.19) <0.001 76.84 (16.42) <0.001
  Female 2151 0.77 (0.25) 73.45 (18.24)
BMI (kg/m2)
  <30 6882 0.86 (0.19) <0.001 76.94 (16.38) <0.001
  30+ 2096 0.78 (0.25) 73.06 (18.34)
Heart rate (beats/min)
  <70 5151 0.85 (0.20) <0.001 76.59 (16.83) <0.001
  70–79 2493 0.84 (0.21) 76.09 (16.35)
  80–89 1004 0.82 (0.23) 74.50 (17.75)
  90+ 330 0.81 (0.22) 71.59 (19.28)
Smoking status
  Never 3378 0.84 (0.21) 0.71 76.21 (17.01) 0.04
  Former 4351 0.85 (0.21) 76.26 (16.79)
  Current 1247 0.84 (0.22) 74.73 (17.22)
Years in education
  No formal education 355 0.79 (0.24) <0.001 72.58 (19.48) <0.001
  1–9 2692 0.82 (0.22) 75.66 (16.74)
  10–12 2805 0.84 (0.22) 75.38 (17.27)
  13–15 1568 0.86 (0.19) 76.97 (16.12)
  16+ 1453 0.89 (0.18) 77.87 (16.45)
Type of index MI
  STEMI 4699 0.86 (0.20) <0.001 76.83 (16.49) <0.001
  NSTEMI 3749 0.82 (0.22) 74.74 (17.59)
  Unknown 530 0.84 (0.21) 78.09 (15.43)
Management of index MI
  PCI 7243 0.85 (0.21) 0.01 76.45 (16.66) 0.65
  CABG 664 0.83 (0.22) 76.76 (16.01)
  Medical 1071 0.80 (0.22) 72.73 (18.90)
Second prior MI
  No 8057 0.85 (0.21) <0.001 76.46 (16.66) <0.001
  Yes 921 0.81 (0.23) 72.28 (18.74)
Diabetes
  No diabetes 5978 0.86 (0.20) <0.001 76.95 (16.36) <0.001
  Non- insulin- treated diabetes 2078 0.84 (0.21) 75.38 (17.34)
  Insulin- treated diabetes 863 0.77 (0.26) 71.50 (18.66)
CKD
  No 8291 0.85 (0.21) <0.001 76.46 (16.69) <0.001
  Yes 687 0.78 (0.25) 70.87 (18.92)
History of major bleed
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instrument with five dimensions of health (mobility, 
self- care, usual activities, pain and discomfort, anxiety 
and depression), for which there are three levels of 
response (no problems, some problems, severe prob-
lems). The EQ- 5D- 3L profiles reported by each patient 
were combined with health state preference values from 
the UK general population,17 to give EQ- 5D- 3L health 
state index scores on a scale anchored at 0 (equivalent 
to death) and 1 (perfect health). Patients were also 
asked to report their own health status on the EQ- 5D 
Visual Analogue Scale (VAS) from 0 (worst health you 
can imagine) to 100 (best health you can imagine). In 
CV disease, the EQ- 5D- 3L has been used widely interna-
tionally and found to have strong convergent validity with 
other HRQoL measures, and good discriminant ability in 
detecting differences in health status.1 At each contact, 
patients were also asked to recall hospitalisations and 
N
EQ- 5D index score, mean 
(SD) P value EQ- 5D VAS score, mean (SD) P value
  Yes 253 0.78 (0.26) 74.35 (16.17)
PAD
  No 8379 0.85 (0.20) <0.001 76.48 (16.66) <0.001
  Yes 599 0.75 (0.25) 69.64 (19.31)
Heart failure
  No 7947 0.85 (0.20) <0.001 76.79 (16.44) <0.001
  Yes 1031 0.77 (0.26) 70.17 (19.40)
Anaemia
  No 8721 0.85 (0.21) <0.001 76.22 (16.81) <0.001
  Yes 257 0.73 (0.26) 69.55 (19.61)
Angina
  No 8086 0.85 (0.20) <0.001 76.70 (16.51) <0.001
  Yes 892 0.76 (0.24) 69.92 (19.32)
Stroke
  No 8576 0.85 (0.21) <0.001 76.25 (16.79) <0.001
  Yes 402 0.76 (0.25) 71.36 (19.24)
Cardiovascular event (last 6 months)
  No 8544 0.85 (0.21) <0.001 76.41 (16.63) <0.001
  Yes 434 0.79 (0.23) 68.53 (20.77)
ER visit (last 6 months)
  No 8466 0.85 (0.21) <0.001 76.42 (16.69) <0.001
  Yes 512 0.76 (0.24) 69.58 (19.51)
COPD
  No 8335 0.85 (0.21) <0.001 76.44 (16.77) <0.001
  Yes 643 0.77 (0.24) 70.66 (18.14)
Prior peptic ulcer
  No 8684 0.85 (0.21) <0.001 76.21 (16.83) <0.001
  Yes 294 0.78 (0.26) 70.58 (19.08)
Diuretics
  No 6599 0.86 (0.20) <0.001 77.28 (16.46) <0.001
  Yes 2258 0.79 (0.24) 72.29 (17.72)
Region
  Asia and Australia 2799 0.89 (0.17) <0.001 77.64 (14.95) <0.001
  Europe 4098 0.83 (0.22) 73.39 (18.01)
  North America 981 0.82 (0.23) 77.47 (17.38)
  Latin America 1100 0.81 (0.23) 80.49 (15.50)
BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; EQ- 
5D, EuroQol-5 dimension; ER, emergency room; MI, myocardial infarction; NSTEMI, non- ST- elevation myocardial infarction; PAD, peripheral artery 
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visits to the emergency room (ER), general practitioner 
(GP), cardiologist or other specialists over the previous 6 
months. These healthcare encounters were summed to 
report each patient’s resource use over 2- years’ follow- up. 
If a death occurred, efforts were made to identify the 
cause (CV or non- CV related). The primary endpoint of 
the TIGRIS Study was a composite comprising CV death, 
MI, stroke and unstable angina requiring urgent revas-
cularisation. All outcome events and resource use meas-
ures were confirmed by the treating physician or hospital, 
including determination of final diagnosis, primary cause 
of hospitalisation, duration of hospital stay, procedures 
and interventions.
Statistical analysis
We summarised the responses to the EQ- 5D- 3L question-
naire at baseline enrolment according to the number 
(%) of patients reporting ‘some’ or ‘severe’ problems 
for each dimension, and by reporting histograms for the 
resulting index scores and VAS scores. The EQ- 5D index 
score had a right- skewed distribution18 and had several 
spikes in its distribution (figure 1). Hence, it has been 
grouped into four ordered categories: <0.60 (lowest 
HRQoL); 0.60–0.74 0.75–0.99; and 1 (highest HRQoL). 
Similarly, we grouped responses to the EQ- 5D VAS score 
into five ordered categories: <60; 60–69; 70–79; 80–89; 
and ≥90 which represent ‘lowest’ to ‘highest’ self- rated 
health status.
We estimated the association of clinical factors with 
the index score category at enrolment using an ordinal 
logistic regression model. We reported the common OR 
of being in a ‘lower’ versus ‘higher’ index score cate-
gory according to the presence versus absence of each 
Table 2 Multivariable model for factors associated with 
EQ- 5D index score as an ordinal measure with categories 
1, 0.75–0.99, 0.60–0.74, <0.60, selected by a stepwise 
regression procedure using p<0.01 for inclusion
Variable
Common OR* 
(95% CI) P value
Female 1.94 (1.76 to 2.14) <0.001
Age (years)
  <70 Reference group <0.001
  70–80 1.25 (1.14 to 1.36)
  80+ 2.01 (1.72 to 2.35)
BMI ≥30 kg/m2 1.57 (1.42 to 1.73) <0.001
Heart rate (beats/min)
  <70 Reference group <0.001
  70–79 1.10 (1.00 to 1.21)
  80–89 1.26 (1.10 to 1.43)
  90+ 1.42 (1.15 to 1.75)
Smoking status
  Never Reference group <0.001
  Former smoker 1.12 (1.02 to 1.23)
  Current smoker 1.30 (1.14 to 1.48)
Years in education
  16+ Reference group <0.001
  13–15 1.20 (1.04 to 1.38)
  10–12 1.45 (1.28 to 1.65)
  1–9 1.52 (1.33 to 1.73)
  No formal education 1.82 (1.46 to 2.27)
Angina 1.85 (1.62 to 2.10) <0.001
Diabetes
  No diabetes Reference group <0.001
  Non- insulin- treated 
diabetes
1.08 (0.98 to 1.19)
  Insulin- treated diabetes 1.52 (1.32 to 1.74)
Stroke 1.69 (1.40 to 2.03) <0.001
PAD 1.64 (1.40 to 1.91) <0.001
ER visit (last 6 months) 1.62 (1.38 to 1.92) <0.001
Prior peptic ulcer 1.40 (1.12 to 1.75) 0.003
COPD 1.44 (1.24 to 1.68) <0.001
Heart failure 1.36 (1.19 to 1.55) <0.001
Anaemia 1.49 (1.18 to 1.88) 0.001
Type of index MI
  STEMI Reference group <0.001
  NSTEMI 1.21 (1.11 to 1.31)
  Unknown 1.32 (1.11 to 1.58)
Diuretics 1.36 (1.23 to 1.50) <0.001
Region




(95% CI) P value
  Asia and Australia 0.60 (0.54 to 0.66)
  North America 0.93 (0.81 to 1.07)
  Latin America 1.14 (1.00 to 1.29)
*Estimated using an ordinal logistic regression model. 
A common OR >1 means that category of patients has 
a poorer self- rated health compared with others (or 
compared with a reference group if the variable has 
>2 categories) after adjusting for the influence of other 
variables in the model. For instance, female patients 
have common OR=1.98, which means that they have 
almost double the odds of being below any cut- off 
value (<1, <0.75 or <0.6) for the EQ- 5D index score 
compared with male patients.
BMI, body mass index; COPD, chronic obstructive 
pulmonary disease; EQ- 5D, EuroQol-5 dimension; ER, 
emergency room; MI, myocardial infarction; NSTEMI, 
non- ST- elevation myocardial infarction; PAD, peripheral 
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risk factor, adjusting for other patient characteristics. We 
retained independent variables in the regression model 
according to a forward stepwise procedure with the 
criteria for an independent association of p<0.01.
We estimated the association of the index score cate-
gory at enrolment with all- cause death, the composite 
CV outcome and each resource use measure. For all- 
cause death and the composite CV endpoint, Poisson 
regression models were used to recognise that rates were 
constant over time. We reported the incidence rate ratios 
and 95% CI for index scores at enrolment in each of the 
three lower categories, versus the category that repre-
sented perfect health. We also reported the association 
of the VAS score at enrolment with all- cause death and 
the CV outcome, and considered the association of the 
index score and VAS score simultaneously, adjusting for 
other factors.
We reported the association of the index score cate-
gory and VAS score at enrolment with resource use up to 
2 years for patients who survived up to 2 years and who 
had complete resource use data. Although each of these 
resource use measures had a right- skewed distribution, 
we used Ordinary Least Squares regression relying on the 
central limit theorem, to adjust for patient characteristics 
in reporting the mean resource use for each index score 
category as the requisite asymptotic assumptions were 
plausible, given the sample size.19 For each model, we 
adjusted for those patient characteristics previously iden-
tified in the TIGRIS Study as predictive of prognosis.20 
We took the same approach in reporting incidence rate 
ratios according to the independent association of each 
of the five EQ- 5D health state dimensions at enrolment 
with both all- cause death and the composite CV outcome, 
adjusting for other factors.
Finally, we estimated the association of CV events (MI, 
stroke, unstable angina requiring urgent revasculari-
sation, bleeding event requiring hospitalisation) that 
occurred between enrolment and 1- year’s follow- up with 
the mean (95% CI) changes in the EQ- 5D index score, 
and the EQ- 5D VAS score over the same time period. We 
reported associations for those patients with complete 
data, which assume that HRQoL data were missing at 
random, conditional on the variables included in the 




A total of 8978 (99.5%) patients completed EQ- 5D ques-
tionnaires at enrolment. Table 1 presents key baseline 
characteristics with accompanying mean EQ- 5D index 
and VAS scores (see also online supplemental table 1 for 
a fuller list of baseline variables). Before adjustment for 
Figure 2 The associations of (A) baseline EQ- 5D index score and (B) baseline VAS score with mortality and the composite 
outcome of CV death, MI, stroke and unstable angina requiring urgent revascularisation (using Poisson regression models with 
and without adjustment for other patient variables). Adjusted for variables in the TIGRIS index model: age ≥65 years; diabetes; 
second prior MI; chronic kidney disease; heart failure; peripheral artery disease; CV event in past 6 months; prior major bleed; 
medical management only of index MI; on diuretics at enrolment. CV, cardiovascular; EQ- 5D, EuroQol-5 dimension; MI, 
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potential confounding factors, female sex, increasing age 
and presence of each comorbidity were each associated 
with lower mean index and VAS scores. For example, the 
mean HRQoL index score for men was 0.87 vs 0.77 for 
women.
Figure 1A shows the proportion of patients at study 
enrolment who reported ‘moderate’ or ‘severe’ problems 
according to each EQ- 5D dimension. Pain and discomfort 
had the highest prevalence (33.1% ‘moderate’ and 2.7% 
‘severe’ problems) followed by ‘mobility’ (24.4% and 
0.2%, respectively). Over half (52%) of patients reported 
a ‘moderate’ or ‘severe’ problem on at least one of the 
EQ- 5D dimensions. Figure 1B summarises EQ- 5D index 
scores at enrolment and shows that 48% of patients had 
scores of 1 (perfect health), 26% between 0.75 and 0.99, 
18% between 0.60 and 0.74%, and 8% less than 0.60.
Associations with index score at enrolment
Table 2 reports the independent association of each factor 
with the index score category at enrolment in a multi-
variable model. Compared with men, women were more 
likely to have lower index scores, with an OR of 1.94 (95% 
CI 1.76 to 2.14). Other factors significantly associated 
with a lower index score were older age, obesity, current 
or ex- smoker, higher heart rate, less formal education, 
presence of each comorbidity (angina, insulin- treated 
diabetes mellitus, stroke, peripheral artery disease, prior 
peptic ulcer, chronic obstructive pulmonary disease, 
heart failure), ER visit in the previous 6 months and 
index MI unknown or NSTEMI (vs STEMI). When the 
VAS score rather than the index score was used as the 
summary measure of HRQoL, the results were similar 
(see online supplemental table 2). There were regional 
differences in the index score (lowest in Latin America, 
highest in Asia/Australia), whereas the VAS score was 
lowest in Europe and highest in Latin America.
Impact of HRQoL on prognosis
Lower EQ- 5D index scores were associated with higher 
risk of all- cause death and the composite outcome of CV 
death, MI, stroke and unstable angina requiring urgent 
revascularisation (figure 2A) over 2- years’ follow- up. 
Patients with an index score of less than 0.60 and those 
with scores of 0.60–0.74 had rate ratios of all- cause death 
of 3.09 (95% CI 2.20 to 4.31) and 1.49 (95% CI 1.07 to 
2.07), respectively, compared with those with an index 
score of 1, after adjustment for differences in other 
patient characteristics at enrolment. The corresponding 
rate ratios for the composite outcome were 2.31 (95% CI 
1.76 to 3.03) and 1.43 (95% CI 1.12 to 1.82), respectively. 
The relationships between HRQoL at enrolment and 
both sets of subsequent outcomes were similar when the 
VAS score rather than the index score was used to predict 
subsequent outcomes (figure 2B). When the association 
of both HRQoL measures were considered simultane-
ously, the index score was independently associated with 
increased mortality risk (p<0.001), while the VAS score 
was not (p=0.84).
After adjustment for patient characteristics at enrol-
ment, the EQ- 5D dimensions that most strongly associ-
ated with all- cause death were problems with ‘self- care’ 
and ‘mobility’ (table 3), with estimated ORs of 1.70 (95% 
CI 1.'26 to 2.29) and 1.52 (1.14 to 2.03), respectively. The 
EQ- 5D dimensions of ‘pain/discomfort’ and ‘usual activi-
ties’ were most strongly associated with the composite CV 
outcome. figure 3A reports the association of index scores 
Table 3 The associations of the five specific problems in the EQ- 5D on (A) all- cause death and (B) the composite outcome 
of CV death, MI, stroke and unstable angina requiring urgent revascularisation (using Poisson regression models with and 
without adjustment for other patient variables)
Unadjusted rate ratio (95% CI) P value Adjusted* rate ratio (95% CI) P value
A
The specific problems
  Mobility 2.26 (1.69 to 3.02) <0.001 1.52 (1.14 to 2.03) 0.004
  Self- care 1.81 (1.35 to 2.43) <0.001 1.70 (1.26 to 2.29) 0.001
  Usual activities 1.48 (1.13 to 1.94) 0.005 1.18 (0.90 to 1.54) 0.24
  Pain/discomfort 1.13 (0.90 to 1.41) 0.28 1.12 (0.90 to 1.39) 0.30
  Anxiety/depression 0.79 (0.62 to 1.01) 0.06 0.91 (0.71 to 1.16) 0.44
B
The specific problems
  Mobility 1.39 (1.10 to 1.74) 0.005 1.14 (0.90 to 1.43) 0.28
  Self- care 1.13 (0.86 to 1.48) 0.39 1.11 (0.84 to 1.36) 0.47
  Usual activities 1.54 (1.24 to 1.91) <0.001 1.30 (1.05 to 1.62) 0.02
  Pain/discomfort 1.41 (1.19 to 1.67) <0.001 1.35 (1.14 to 1.60) <0.001
  Anxiety/depression 0.89 (0.74 to 1.08) 0.23 0.94 (0.78 to 1.14) 0.55
*Adjusted for variables in the TIGRIS risk index model: age ≥65 years, diabetes, second prior MI, chronic kidney disease, heart failure, peripheral 
artery disease, CV event in past 6 months, prior major bleed, medical management only of index MI, on diuretics at enrolment.
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at enrolment with resource use over 2- years’ follow- up 
for the 7846 patients who survived to that timepoint and 
provided complete information. A further 296 patients 
died, and 840 patients had missing resource use data. 
Lower index and VAS scores at enrolment were associ-
ated with higher subsequent use of healthcare resources, 
before and after adjustment for other patient character-
istics at enrolment (figure 3B). For example, compared 
with patients who were in ‘perfect health’ at enrolment, 
the mean numbers of hospitalisations for any reason were 
89% higher for patients with index score less than 0.60 
and 81% higher for index score between 0.60 and 0.74. 
Similar patterns emerged for CV- specific hospitalisations, 
ER visits, visits to the GP and visits to other specialists, but 
in contrast, visits to cardiologists were less common for 
those with lower HRQoL.
Changes in index score over time
Among survivors, there is no evidence of an overall change 
in the index score over time. For the 5932 patients with 
the EQ- 5D recorded at every 6- monthly visit, the mean 
index score was 0.87 at all four follow- up visits vs 0.86 at 
baseline. For the 2754 patients who were alive at the end 
of the follow- up period, but missed at least one visit, the 
mean index score at baseline was 0.83.
The estimated effect of non- fatal CV and bleeding 
events on a patient’s change in self- rated health over 1 
year is shown in table 4. MI, unstable angina requiring 
revascularisation and a bleeding event requiring hospital-
isation occurred in 103, 52 and 46 patients, respectively, 
and all events were associated with a deterioration in self- 
rated health. Stroke occurred in 28 patients but showed 
less impact on self- rated health. These effects were more 
marked for change in VAS score than for the change in 
index score, but the patterns were similar.
DISCUSSION
This prospective study of HRQoL 1–3 years post- MI 
included almost 9000 patients from 25 countries in four 
Figure 3 Health resource use over 2- years’ follow- up by baseline self- rated health in 7846 patients with health resource data 
at every visit (using OLS regression models with and without adjustment for other patient variables). (A) EQ- 5D index score 
and (B) EQ- 5D VAS score adjusted for variables in the TIGRIS index model: age ≥65 years; diabetes; second prior MI; chronic 
kidney disease; heart failure; peripheral artery disease; CV event in past 6 months; prior major bleed; medical management 
only of index MI; on diuretics at enrolment. CV, cardiovascular; EQ- 5D, EuroQol-5 dimension; ER, emergency room; GP, general 
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continents. The TIGRIS Study was designed to assess 
the association of clinical factors with HRQoL at enrol-
ment, the effect of HRQoL on subsequent outcomes and 
resource use, and the change in HRQoL associated with 
CV events. After adjustment for a full range of patient 
factors using a previously validated risk model,20 the study 
found that HRQoL was associated with chronic comor-
bidities, being female, age >80 years, being obese, fewer 
years in education and having an NSTEMI index event. 
A lower index score category at enrolment was associ-
ated with a higher subsequent risk of all- cause death, 
of a major CV event and more hospitalisations over the 
2- years’ follow- up period. Patients who experienced 
any CV event had a reduction in the mean index score 
between enrolment and 1- year’s follow- up.
We found that the EQ- 5D index score at enrolment 
was on average 0.87 for men vs 0.77 for women, and 
women were more likely to have lower EQ- 5D index 
scores after adjustment for other factors. In an age−sex 
matched general population, the corresponding index 
scores were 0.78 for men and 0.77 for women.21 HRQoL 
post- MI may be lower for women than men because of a 
different profile of symptoms in the post- MI period22 and 
lower access to cardiac rehabilitation services.23 Previous 
studies reported that women have lower HRQoL than 
men post- MI but were focused on specific countries and 
did not consider HRQoL 1–3 years post- MI.3 13 23 24
Previous studies have also found that following MI, HRQoL 
is lower in older patients, following NSTEMI and for patients 
with comorbidities.5 25 Lower HRQoL in NSTEMI has been 
attributed to more symptomatic disease, a history of angina 
and multimorbidity.5 23 Previous research has found that 
for chronic disease, more generally, obesity, lower socioeco-
nomic status and presence of comorbidities are associated 
with lower HRQoL.26–28 Our study is unique in finding that 
these risk factors were independently associated with HRQoL 
in the context of a large multinational study. We also found 
that the mean index score was lower for patients attending 
centres in Latin America and higher for those in Asia, but it is 
unclear whether this reflects differences in patient manage-
ment, severity of their initial MI or other regional features.
Our study shows the importance of HRQoL measured 
1–3 years after MI in predicting future events and resource 
use. We found that poorer HRQoL (ie, a lower EQ- 5D 
index score) predicted a higher risk of all- cause death and 
a composite of major CV events. While VAS score catego-
ries also predicted these outcomes, the associations were 
weaker, and when both scores were considered simulta-
neously, the VAS score was not independently associated 
with these outcomes. Methodological guidelines also 
support the use of the index score in preference to the 
VAS score.2 Consistent with a previous systematic review 
of the use of EQ- 5D in CVD,3 we found that the presence 
of problems on the ‘self- care’ and ‘mobility’ dimensions 
of the EQ- 5D index were most strongly associated with all- 
cause mortality, whereas problems on the ‘pain/discom-
fort’ and ‘usual activities’ dimensions were most strongly 
associated with CV events.
This study estimated the effect of CV events on changes 
in EQ- 5D index scores between enrolment and 1- year's 
follow- up. Our finding that ‘any CV event’, MI, unstable 
angina and bleeding event requiring hospitalisation were 
each associated with a mean reduction in the index score 
is consistent with previous studies.5–11 22 The PEGASUS- 
TIMI 54 trial reported decrements of similar magni-
tude.29 Our study also added to the limited literature 
that has reported that lower index scores are associated 
with increased mean number of hospitalisations and ER 
visits.8 Future studies could use these estimates in cost- 
effectiveness models that evaluate new treatments for 
stable patients following MI.
The main strengths of the study are the large sample 
size, wide spread of centres, prospective design and use 
of a validated risk adjustment model when examining the 
Table 4 Influence of clinical events over 1 year on change in self- rated health at 1 year
N Mean change* (95% CI) P value
A Change in EQ- 5D index score
  Any event 223 −0.04 (−0.07 to −0.02) <0.001
  MI 103 −0.04 (−0.07 to −0.01) 0.02
  Stroke 28 0.01 (−0.05 to 0.08) 0.68
  Unstable angina requiring urgent revascularisation 52 −0.06 (−0.10 to −0.01) 0.02
  Bleeding event requiring hospitalisation 46 −0.04 (−0.09 to 0.01) 0.15
B Change in EQ- 5D VAS score
  Any event 221 −3.37 (−5.57 to −1.17) 0.003
  MI 102 −4.02 (−6.63 to −1.41) 0.003
  Stroke 27 −3.67 (−8.70 to 1.37) 0.15
  Unstable angina requiring urgent revascularisation 52 −7.87 (−11.51 to −4.23) <0.001
  Bleeding event requiring hospitalisation 46 −5.57 (−9.44 to −1.71) 0.005
*Adjusted for other baseline predictors and estimated using an OLS regression model.
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association of HRQoL score with subsequent outcomes. 
A limitation is that CV events during the follow- up period 
were identified at each centre but were not confirmed 
by an independent event validation committee. Also, the 
finding that HRQoL was not significantly lower following 
stroke may reflect that only few (n=32) patients had 
this event over 1- year’s follow- up. Also, as assessment of 
HRQoL at enrolment was at least 1- year post- MI, those 
who died within a year or did not consent to participate, 
were excluded. Further research is required to consider 
the association of HRQoL following MI with subsequent 
outcomes over longer time periods.
CONCLUSIONS
In a large global population of patients enrolled 1–3 
years post- MI, self- reported health status provided valu-
able insights. First, HRQoL is associated with both objec-
tive evidence of disease and sociodemographic character-
istics. Second, poorer HRQoL is strongly associated with 
increased hospitalisations. Third, poorer HRQoL 1–3 
years after MI is an independent predictor of CV events 
and all- cause death. We recommend that clinical manage-
ment post- MI should pay greater attention to patients’ 
perceptions of their own health status.
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